Galectin Therapeutics (GALT) Competitors $1.53 +0.12 (+8.51%) Closing price 02/18/2025 04:00 PM EasternExtended Trading$1.56 +0.03 (+1.90%) As of 02/18/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GALT vs. CRVS, PRME, ATYR, MNPR, TRVI, ALLO, CMPS, KRRO, OLMA, and FHTXShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Corvus Pharmaceuticals (CRVS), Prime Medicine (PRME), Atyr PHARMA (ATYR), Monopar Therapeutics (MNPR), Trevi Therapeutics (TRVI), Allogene Therapeutics (ALLO), COMPASS Pathways (CMPS), Korro Bio (KRRO), Olema Pharmaceuticals (OLMA), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Corvus Pharmaceuticals Prime Medicine Atyr PHARMA Monopar Therapeutics Trevi Therapeutics Allogene Therapeutics COMPASS Pathways Korro Bio Olema Pharmaceuticals Foghorn Therapeutics Corvus Pharmaceuticals (NASDAQ:CRVS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends. Is CRVS or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Galectin Therapeutics N/A N/A -163.15% Which has preferable valuation & earnings, CRVS or GALT? Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-5.13Galectin TherapeuticsN/AN/A-$41.07M-$0.73-2.10 Which has more volatility and risk, CRVS or GALT? Corvus Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Does the MarketBeat Community believe in CRVS or GALT? Galectin Therapeutics received 56 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. However, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 59.11% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Galectin TherapeuticsOutperform Votes34759.11% Underperform Votes24040.89% Do analysts recommend CRVS or GALT? Corvus Pharmaceuticals presently has a consensus target price of $12.38, suggesting a potential upside of 159.43%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 618.95%. Given Galectin Therapeutics' higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to CRVS or GALT? In the previous week, Galectin Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Galectin Therapeutics and 1 mentions for Corvus Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 0.20 beat Corvus Pharmaceuticals' score of -0.50 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Corvus Pharmaceuticals Negative Galectin Therapeutics Neutral Do institutionals and insiders hold more shares of CRVS or GALT? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCorvus Pharmaceuticals beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.49M$6.91B$5.80B$9.22BDividend YieldN/A2.89%5.27%3.98%P/E RatioN/A3.3518.7915.83Price / SalesN/A352.99479.0583.70Price / CashN/A75.6346.0538.28Price / Book-1.515.547.145.01Net Income-$41.07M$164.55M$3.20B$220.98M7 Day Performance16.79%1.73%1.38%2.13%1 Month Performance23.39%1.38%3.47%1.63%1 Year Performance-12.07%-0.12%20.17%16.41% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.293 of 5 stars$1.53+8.5%$11.00+619.0%-12.1%$88.49MN/A0.009News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals2.2774 of 5 stars$5.03-3.5%$12.38+146.0%+108.3%$323.23MN/A-5.4130PRMEPrime Medicine3.1063 of 5 stars$2.42-2.0%$13.13+442.4%-64.7%$317.41MN/A-1.18234Gap UpATYRAtyr PHARMA2.2792 of 5 stars$3.78-3.2%$19.25+409.9%N/A$316.87M$350,000.00-4.0253Analyst ForecastShort Interest ↑News CoverageGap UpMNPRMonopar Therapeutics1.3954 of 5 stars$51.89+7.1%$43.00-17.1%+2,475.6%$316.53MN/A-26.3410TRVITrevi Therapeutics2.9568 of 5 stars$4.06-4.4%$9.31+129.7%+54.6%$311.71MN/A-9.2220Analyst RevisionPositive NewsALLOAllogene Therapeutics2.9449 of 5 stars$1.49-1.7%$9.73+555.4%-40.9%$311.36M$90,000.00-0.95310News CoverageGap UpCMPSCOMPASS Pathways1.8028 of 5 stars$4.48+1.6%$33.60+650.0%-57.8%$306.52MN/A-2.04120Analyst RevisionGap UpKRROKorro Bio0.9618 of 5 stars$32.23-6.9%$144.00+346.8%-44.0%$302.00MN/A0.0070OLMAOlema Pharmaceuticals3.2481 of 5 stars$5.16-9.3%$28.75+457.2%-66.4%$295.67MN/A-2.3670News CoverageFHTXFoghorn Therapeutics2.9252 of 5 stars$5.29+11.4%$13.17+148.9%-8.6%$294.18M$34.15M-2.76120Short Interest ↑Gap UpHigh Trading Volume Related Companies and Tools Related Companies CRVS Alternatives PRME Alternatives ATYR Alternatives MNPR Alternatives TRVI Alternatives ALLO Alternatives CMPS Alternatives KRRO Alternatives OLMA Alternatives FHTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GALT) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.